• 1
    Cosgriff TM, Boudreau EF, Pamplin CL, Doberstyn EB, Desjardins RE, Canfield CJ. Evaluation of the antimalarial activity of the phenanthrenemethanol halofantrine (WR 171, 669). Am J Trop Med Hyg 1982; 31: 231.
  • 2
    Boudreau EF, Pang LW, Dixon KE, et al. Malaria: treatment efficacy of halofantrine (WR 171, 669) in initial field trials in Thailand. Bull World Health Org 1988; 66: 227237.
  • 3
    Watt G, Loesuttiviboon L, Songsakul K, et al. Efficacy and tolerance of extended-dose halofantrine for drug-resistant falciparum malaria in Thailand. Am J Trop Med Hyg 1994; 50: 187192.
  • 4
    Karbwang J, Ward SA, Milton KA, Bangchang KN, Edwards G. Pharmacokinetics of halofantrine in healthy Thai volunteers. Br J Clin Pharmacol 1991; 32: 639640.
  • 5
    Milton KA, Edwards G, Ward SA, Orme M, L' E, Breckenridge AM. Pharmacokinetics of halofantrine in man: effects of food and dose size. Br J Clin Pharmacol 1989; 28: 7177.
  • 6
    Ohrt C, Watt G, Teja-Isavadharm P, et al. Pharmacokinetics of an extended-dose halofantrine regimen in patients with malaria and in healthy volunteers. Clin Pharmacol Ther 1995; 57: 525532.
  • 7
    Karbwang J, Milton KA, Bangchang KN, Ward SA, Edwards G, Bunnag D. Pharmacokinetics of halofantrine in Thai patients with acute uncomplicated falciparum malaria. Br J Clin Pharmacol 1991; 31: 484487.
  • 8
    Watkins WM, Winstanley PA, Mberu EK, et al. Halofantrine pharmacokinetics in Kenyan children with non-severe and severe malaria. Br J Clin Pharmacol 1995; 39: 283287.
  • 9
    Humberstone AJ, Porter CJH, Charman WN. A physicochemical basis for the effect of food on the absolute bioavailability of halofantrine. J Pharm Sci 1996; 85: 525529.
  • 10
    Humberstone AJ, Porter CJH, Edwards GA, Charman WN. Association of halofantrine with postprandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state. J Pharm Sci 1998; 87: 936942.
  • 11
    Gimenez F, Gillotin C, Basco LK, et al. Plasma concentrations of the enantiomers of halofantrine and its main metabolite in malaria patients. Eur J Clin Pharmacol 1994; 46: 561562.
  • 12
    Halliday RC, Jones BC, Smith DA, Kitteringham NR, Park BK. An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologus enzyme expression systems. Br J Clin Pharmacol 1995; 40: 369378.
  • 13
    Bryson HM & Goa K. Halofantrine: A review of its antimalarial activity, pharmacokinetic properties and therapeutic potential. Drugs 1992; 43: 236258.
  • 14
    Nosten F, Ter Kuile FO, Luxemburger C, et al. Cardiac effects of antimalarial treatment with halofantrine. Lancet 1993; 341: 10541056.
  • 15
    Castot A, Rapuport P, LeCoz P. Prolonged QT interval with halofantrine (letter). Lancet 1993; 341: 1541.
  • 16
    Monlun E, Pillet O, Cochard JF, Favarel-Garrigues JC, LeBras M. Prolonged QT interval with halofantrine (letter). Lancet 1993; 341: 15411542.
  • 17
    Karbwang J, Na Bangchang K, Bunnay D, Harinasuta T. Cardiac effect of halofantrine. Lancet 1993; 342: 501.
  • 18
    Toivonen L, Vittasalo M, Kiikamaki H, Raatikka M, Pohjula-Sintonen S. Provocation of ventricular tachycardia by antimalarial drug halofantrine in congenital long QT syndrome. Clin Cardiol 1994; 17: 403404.
  • 19
    Touze JE, Bernard J, Keundjian A, et al. Electrocardiographic changes and halofantrine plasma level during acute falciparum malaria. Am J Trop Med Hyg 1996; 54: 225228.
  • 20
    Matson PA, Luby SP, Redd SC, Rulka HR, Meriwether RA. Cardiac effects of standard-dose halofantrine therapy. Am J Trop Med Hyg 1996; 54: 229231.
  • 21
    Gundersen SG, Rostrap M, Von Der Lippe E, Platou ES, Myrvang B, Edwards G. Halofantrine-associated ventricular fibrillation in a young woman with no predisposing QTc prolongation. Scand J Infect Dis 1997; 29: 207208.
  • 22
    Wesche DL, Chen Y, Wang W, Schuster BG, Woosley RL. Mechanism of cardiotoxicity of halofantrine. Program Abstract of 44th Ann Mtg Am Soc Trop Med Hyg 1995; Abstract 350: 202.
  • 23
    Karle JM. X-ray crystal structure of the antimalarial agent (−)-halofantrine hydrochloride supports stereospecificity for cardiotoxicity. Antimicrob Agents Chemother 1997; 41: 791794.
  • 24
    Gimenez F, Aubry A-F, Farinotti R, Kirkland K, Wainer IW. The determination of the enantiomers of halofantrine and monodesbutylhalofantrine in plasma and whole blood using sequential achiral/chiral high performance liquid chromatography. J Biomed Pharm Anal 1992; 10: 245250.
  • 25
    Sale ME, Barbey JT, Woosley RL, et al. The electrocardiographic effects of cetirizine in normal subjects. Clin Pharmacol Ther 1994; 56: 296301.
  • 26
    Woosley RL & Sale M. QT interval: a measure of drug action. Am J Cardiol 1993; 72: 36B−43B.
  • 27
    Fridericia LS. Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken. Acta Med Scand 1920; 53: 469486.
  • 28
    Bazett HC. An analysis of the time relations of electrocardiograms. Heart 1920; 7: 353370.
  • 29
    Lepeschkin E & Surawicz B. The measurement of the Q-T interval of the electrocardiogram. Circulation 1952; 51: 378.
  • 30
    Abernethy DR, Greenblatt DJ, Divoll M, Shader RI. Prolonged accumulation of diazepam in obesity. J Clin Pharmacol 1983; 23: 369376.
  • 31
    Marquardt DW. An algorithm for least-squares estimation of non-linear parameters. J Soc Ind Appl Math 1963; 11: 431441.
  • 32
    Holford NHG & Sheiner LB. Pharmacokinetic and pharmacodynamic modeling in vivo. CRC Crit Rev Bioeng 1981; 5: 273322.